From: Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials
Certainty assessment | Number of patients | Effect | Certainty | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
№ of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Anti-hypertensives withdrawal | Anti-hypertensives continuation | Relative (95% CI) | Absolute (95% CI) | |
Number of patients with systolic blood pressure < 150 mmHg (mean follow up: 12 weeks) | |||||||||||
1 [21] | Open label RCT | Serious | Not serious | Not serious | Not serious | None | 229/265 (86.4%) | 236/269 (87.7%) | RR 0.98 (0.92 to 1.05) | 18 fewer per 1000 (70 fewer to 44 more) | ⨁⨁⨁◯ MODERATE |
Quality of life (mean follow up: 12 weeks; assessed with: EQ-5D-5L Index) | |||||||||||
1 [21] | Open label RCT | Serious | Not serious | Not serious | Not serious | None | 260 | 263 | – | MD 0.01 lower (0.03 lower to 0.01 higher) | ⨁⨁⨁◯ MODERATE |
Frailty (assessed with: Frailty Index) | |||||||||||
1 [21] | Open label RCT | Serious | Not serious | Not serious | Not serious | None | 282 | 287 | – | MD 0.00003 lower (0.0005 lower to 0.005 higher) | ⨁⨁⨁◯ MODERATE |
Cardiovascular risk | |||||||||||
1 [22] | Open label RCT | Serious | Not serious | Not serious | Not serious | None | 492 | 575 | – | MD 0.1 higher (0.4 lower to 0.7 lower) | ⨁⨁⨁◯ MODERATE |